Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aethlon Medical Inc

Aethlon Medical's Hemopurifier set to revolutionize cancer therapy and COVID-19 treatment
Current Analysis:
Aethlon Medical, a medical therapeutic company, has advanced two clinical stage devices that are designed to treat life-threatening infectious diseases and cancer called the Hemopurifier. The device is said to be capable of clearing exosomes that spread cancer or other viral infections through multiple mechanisms. The FDA has approved the device and designated it as a "Breakthrough Device" for two independent indications. The medical company is planning to conduct clinical trials in Australia for the use of Hemopurifier in treating solid tumors, head and neck cancer, gastrointestinal cancers, and other cancers.

Forward-Looking Analysis:
Aethlon Medical is also currently testing the efficacy of Hemopurifier in COVID-19 treatments, with the first patient enrolled and having completed the Hemopurifier treatment phase of the protocol earlier this year. The company has launched a wholly-owned subsidiary in Australia formed, which aims to conduct clinical research, seek regulatory approval, and commercialize Hemopurifier. Despite the Hemopurifier being a promising device in cancer and viral infection treatment, Aethlon Medical is facing disruptions in their Hemopurifier supply. However, with the company's innovative and effective technologies, they are set to revolutionize the cancer therapy and COVID-19 treatment industry.

Announcement: AEMD 10-Q Quarterly Report